Alnylam Pharmaceuticals, Inc.
Revenue Breakdown
| Fiscal Year | ONPATTRO | AMVUTTRA | GIVLAARI | OXLUMO | Collaboration and other revenue | Royalty revenue |
|---|---|---|---|---|---|---|
| FY2020 | $306.1M | $0 | $55.1M | $333.0K | $131.3M | $0 |
| FY2021 | $474.7M | $0 | $127.8M | $59.6M | $181.0M | $1.2M |
| FY2022 | $557.6M | $93.8M | $173.1M | $69.8M | $134.9M | $8.2M |
| FY2023 | $354.5M | $557.8M | $219.3M | $109.8M | $546.2M | $40.6M |
| FY2024 | $252.9M | $970.5M | $255.9M | $167.1M | $510.2M | $91.8M |
| FY2025 | $172.8M | $2.31B | $308.5M | $191.4M | $553.4M | $174.0M |